There has been increasing interest in the identification of novel HIV entry inhibitors. For the discovery of these entry inhibitors, robust surrogate anti-HIV assays are highly desired. The authors report a novel anti-HIV assay system using Moloney murine leukemia viruses (MMLVs) pseudotyped with cytoplasmic tail-truncated HIV envelope protein gp140. These pseudotyped MMLV-HIVgp140 viral particles carry luciferase transcripts; therefore, robust luciferase signal can be detected in cells infected by these pseudotypes. Polycationic agent polybrene and spinoculation markedly enhanced the infection efficiency of these pseudotypes. It was demonstrated that the tropism of these pseudotypes is dependent on the pseudotyped HIV envelope proteins. MMLV viruses pseudotyped with gp140 from an R5 HIV virus specifically infect CCR5-expressing cells, and viruses pseudotyped with gp140 from an X4 HIV virus specifically infect CXCR4-expressing cells. Furthermore, CCR5 antagonists inhibited only MMLV-gp140(R5) infections, and CXCR4 antagonists inhibited only MMLV-gp140(X4) infections. A variety of known HIV entry inhibitors were tested in both R5-and X4-dependent pseudotype antiviral assays, and the IC 50 values generated were consistent with published results. The pseudotype antiviral assay was also used in the characterization of hundreds of novel CCR5 antagonists. The IC 50 values determined in this assay were compared with those determined in HIV antiviral and cell-cell fusion (CCF) assays, and good correlation was found between pseudotype antiviral assay and HIV antiviral assay (R 2 = 0.9) or CCF assay (R 2 = 0.8). (Journal of Biomolecular Screening 2006:652-663) 
INTRODUCTION

H
IV ENTERS HOST CELLS via the interaction of the viral envelope (Env) proteins gp160 and the host cell membrane proteins. The HIV-1 Env is a type I integral membrane protein that mediates viral attachment and membrane fusion, and it is also the target for neutralizing antibodies. Synthesized as a single polypeptide precursor, Env is subsequently cleaved by a cellular serine protease to generate 2 noncovalently associated subunits, gp120 and gp41. The gp120 binds to the cell surface, whereas the membrane-spanning gp41 subunit is responsible for membrane fusion. The primary receptor for HIV-1 is CD4; however, binding of the gp120 subunit to CD4 by itself does not trigger membrane fusion. 1 Binding to CD4 results in conformational changes in gp120 that enable it to bind a second receptor, termed a coreceptor, which leads to membrane fusion. 2, 3 Most primary HIV-1 strains use the chemokine receptor CCR5 as coreceptor (termed R5 virus), whereas some viruses are able to use another chemokine receptor CXCR4 as coreceptor (termed X4 virus) or use both CCR5 and CXCR4 as coreceptors (termed R5X4 virus). viral membrane in close proximity to the cell membrane and results in the formation of a fusion pore. There is little knowledge about the role of the long cytoplasmic tail (CT) of gp41 in this fusion process. However, published data suggest that HIV or SIV variants with a truncated cytoplasmic domain of gp41 increase in Env fusogenicity. [8] [9] [10] [11] There has been a growing interest in new anti-HIV agents to tackle the increasing problems of multidrug resistance. Host and viral molecules involved in various stages of HIV entry have been explored as novel targets for the discovery of anti-HIV agents. 4, [12] [13] [14] Enfuvirtide (ENF; T20) is the 1st HIV entry inhibitor in the market. ENF is a peptide inhibitor that targets the trimeric coiled coil formed by HR1, thus preventing the formation of the 6-helix bundle.
14 Recently, HIV coreceptor CCR5 has been particularly favored as a novel drug target. 13 A number of CCR5 antagonists have been identified and have demonstrated potent antiviral effects both in cell culture and in clinical trials. 13, 15, 16 In addition, many other small-molecule inhibitors or antibodies targeting other HIV attachment/entry sites are in various stages of development. 12 Therefore, there is a strong need for a universal robust assay system for the identification and characterization of various HIV entry inhibitors.
Antiviral assays using live HIV viruses have to be performed in restricted environments because of biosafety concerns; thus, they are not optimal for large-scale routine screens or structureactivity relationship studies. A biologically safe and highthroughput-compatible surrogate antiviral assay system is highly desired for this purpose. A variety of cell-based surrogate assay systems have been reported that mimic the HIV virus-cell fusion. Basically, these assays fall in the following 2 categories: pseudotyped HIV-cell fusion [17] [18] [19] and cell-cell fusion (CCF). [20] [21] [22] In the pseudotyped HIV-cell fusion assay, an HIV virus or other retrovirus pseudotyped with the envelope proteins from an HIV strain was used to infect indicator cells. Because these pseudotyped viruses are unable to replicate in infected cells and there will be only 1 round of infection, this type of assay is also called a single-cycle antiviral assay. HIV-HI Venv pseudotype antiviral assays 17 are most commonly used for evaluation of HIV entry inhibitors. Here we report an improved Moloney murine leukemia virus (MMLV)-based pseudotype anti-HIV assay system. MMLV is a retrovirus whose modified versions have been commonly used as therapeutic vectors for gene expression. 23 These MMLV-based viral vector particles package viral RNA from which genes required for viral replication have been replaced by therapeutic genes or markers. To generate these viral particles, a packaging cell line is required. The packaging cell line provides viral proteins Gag, Pol, and Env, which are necessary for the assembly of viral particles. These viral proteins are encoded by RNAs that do not contain packaging signals. Therefore, the recombinant viral particles produced this way are able to transfer therapeutic genes but are replication incompetent. The host specificity (tropism) of a retrovirus is determined by the viral surface envelope proteins.
By assembling envelope proteins from a different strain onto the surface of a retrovirus, the tropism of the virus can be changed. This process is called pseudotyping. MMLV viral particles can be pseudotyped with envelope proteins of a variety of viruses including simian sarcoma-associated virus, feline leukemia virus, human T-cell leukemia virus, feline endogenous virus RD114, and vesicular stomatitis virus. [24] [25] [26] [27] Pseudotyping of MMLV viruses with HIV envelope proteins has also been reported. However, only the HIV envelope protein with the intracellular domain of gp41 being truncated (named gp140) was successful in pseudotyping MMLV viruses. 18, 19, 28 These MMLV-HIVgp140 pseudotypes were found to be able to infect HIV host cells. In the current study, MMLV-HIVgp140 pseudotypes were successfully generated from the GP2-293Luc packaging cell line. Robust anti-HIV assays have been developed using MMLV viruses pseudotyped with R5 or X4 HIV envelope proteins. The tropism of these viruses was confirmed to be dependent on the tropism of the pseudotyping HIV envelopes. Furthermore, these pseudotype antiviral assays were validated with various HIV entry inhibitors.
MATERIALS AND METHODS
Reagents
Cell culture media and fetal bovine sera were purchased from Invitrogen (Carlsbad, CA). Human CCR5 monoclonal antibody 2D7, CXCR4 antibody 1D9, CD4 antibody, and phycoerythrin (PE)-conjugated goat antimouse antibodies were purchased from Pharmingen (San Diego, CA). Recombinant HIV gp120 glycoprotein produced in insect cells was purchased from Protein Sciences (Meriden, CT). Anti-gp120 antibody was purchased from Fitzgerald Industries International (Concord, MA). CXCR4 antagonist T22 was purchased from BACHEM Bioscience (Philadelphia, PA). HIV fusion/entry inhibitors AMD3100 (CXCR4 antagonist), SCH-C, SCH-D, Maraviroc (MVC), and GW873140 (AK602), TAK-779, and all other CCR5 small-molecule antagonists were synthesized at Roche Palo Alto (Palo Alto, CA).
Cell lines
The MAGI-R5 (U373-MAGI-CCR5E) and MAGI-X4 (U373-MAGI-CXCR4CEM) indicator cell lines were obtained from the National Institutes of Health (NIH) AIDS Research & Reference Reagents Program. Both MAGI-R5 and MAGI-X4 cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 4 mM glutamine, and 200 µg/ml G418, 1 × Pen-Strep, 100 µg/ml hygromycin B, and 1 µg/ml puromycin. The expression of CD4, CCR5, and CXCR4 on the indicator cell lines was confirmed by fluorescence activated cell sorting (FACS) analyses using appropriate antibodies. Packaging cell line TELCeB6 (provided by F. L. Cosset) 27 produces noninfectious virions that contain the nlslacZ retroviral vector. 23 TELCeB6 cells were maintained in DMEM containing 10% FBS and 1 × Pen/Strep. Packaging cell line GP2-293Luc (BD Biosciences Clontech, Palo Alto, CA) was maintained in DMEM supplemented with 10% FBS, 1 × Pen/Strep, and 4mM L-glutamine. JC53-BL cells that express CD4, CCR5, and CXCR4 (NIH AIDS Research & Reference Reagents Program) were maintained in DMEM supplemented with 10% FBS, 1 × Pen/Strep, and 2 mM L-glutamine).
Expression plasmids
The envelope coding sequences including the rev genes of CXCR4-tropic HIV virus NL-43 and CCR5-tropic HIV virus 92US715 (GenBank accession No. U08451, obtained from NIH AIDS Research & Reference Reagents Program) were amplified using primers 5′-GGTTGCTTTCATTGCCAAGTTT-GTTTC-3′ and 5′-CGCACGCGTACTACTTTTTGACCACTTGCCACC-CAT-3′, and the amplified DNA was cloned into pcDNA3.1/ V5-His-TOPO vector (Invitrogen, Carlsbad, CA). The env gene from NL-43 was also cloned with a Kozak sequence at the translation initiation site (underlined) by using a different upstream PCR primer: 5′-GCCGCCATGGCAGGAAGAAGCGGAGAC AGC-3′. For the expression of the truncated form of gp160, a stop codon was introduced into gp160 using the QuikChange mutagenesis kit (Stratagene, La Jolla, CA). The resulted constructs were named R5-gp140, X4-gp140, and X4-gp140K (X4-gp140 carrying a Kozak sequence), which express HIV-1 92US715 and NL-43 envelope proteins with their cytoplasmic end 144 amino acid residues truncated, respectively.
Production of pseudotyped MMLV-HIVenv viruses
The pseudotyped virus particles were produced by transfecting HIV gp140 expression plasmids described above into packaging cell lines GP2-293luc or TELCeB6. The pseudotyped MMLV-HIVenv viruses from these packaging cells carry either a luciferase (from GP2-293Luc) or a β-galactosidase (from TELCeB6) reporter gene. For the generation of pseudotyped MMLV-HIVenv viruses, the packaging cells were plated in 6-well culture plates at 4 × 10 5 cells per well. On the next day, culture medium was replaced with OPTI-MEM medium 30 min prior to transfection. Transfection reagent Fugene 6 (Roche Applied Sciences, Indianapolis, IN) was used for the transfections following the manufacturer's instructions. Briefly, 12 µl of Fugene 6 was mixed with 2 µg of plasmid DNA in a final volume of 100 µl. After 30 min of incubation, the DNAFugene mixtures were added to GP2-293Luc cultures, followed by gentle mixing. Cultures were replenished with fresh complete growth medium after 6 to 8 h of incubation at 37°C. CalPhos method was also used for optimization of virus production, using the CalPhos Mammalian Transfection Kit (BD Bioscience Clontech, Palo Alto, CA). Briefly, 2 µl of 50 mM chloroquine (Sigma, St. Louis, MO) was added to the culture medium followed by gentle mixing. Transfection mix was made by slowly adding DNA-CaCl 2 solution containing 4 µg of plasmid into 100 µl of 2 × Hepes-buffered saline. The transfection mix was then added to the cells. Culture medium was replaced with fresh growth medium 8 to 12 h posttransfection. The cells were cultured at 32 °C for 48 h. Culture media containing viral particles were harvested and passed through 0.45 µm low-protein-binding filters to eliminate cell debris. Polybrene (Specialty Media, Phillipsburg, NJ) was then added to viral supernatant to a final concentration of 5 µg/ml. After incubation at room temperature for 10 min, the pooled viral supernatants were then aliquoted and stored at -80 °C.
Pseudotype antiviral assays
MAGI-R5 or MAGI-X4 cells were plated in 96-well white culture plates at 1 × 10 4 cells/well and cultured overnight. Cell cultures were changed with fresh media 1 h prior to infection. Viral supernatant was added to the cultures followed by centrifugation of culture plates at 2500 rpm for 45 min at room temperature. The cultures were then incubated at 37 °C overnight after spinoculation. On the next day, the culture medium was replaced with fresh growth medium, and the cells were incubated for another 24 h at 37 °C. At the end of incubation, 25 µl of Steady-Glo luciferase substrate was added into each well, and the cultures were sealed and gently shaken for 45 min. The luciferase activity was measured for 10 s per well as luminescence by using the 16-channel TopCount NXT (PerkinElmer, Shelton, CT) with 10 min dark adaptation, and the readout is count per second. For infections with pseudotypes produced from TELCeB6 cells, the infected MAGI cells were stained for β-galactosidase (β-gal) activity using the β-Gal Staining Kit (Invitrogen, Carlsbad, CA) as described above. The IC 50 was calculated using the sigmoidal dose-response model with one binding site in Microsoft XLFit.
Syncytia formation
TELCeB6 cells were transfected with HIV gp140 expression plasmid using Fugene 6 reagent following the manufacturer's instructions. Twenty-four hours posttransfection, the cells were detached and plated at a 1:1 ratio with either MAGI-CCR5 or MAGI-CXCR4 cells in 48-well plates at 3 × 10 4 cells per well in RPMI medium supplemented with 10% FBS. After 6 h of co-culture, the cells were stained for β-galactosidase (β-gal) activity using the β-Gal Staining Kit (Invitrogen, Carlsbad, CA). Cells were rinsed once with phosphate-buffered saline (PBS), then fixed with PBS containing 2% formaldehyde and 0.2% glutaraldehyde for 10 min at room temperature. The cells were rinsed twice with PBS, stained in PBS containing 4 mM potassium ferricyanide, 4 mM potassium ferrocyanide, 2 mM magnesium chloride, and 1 mg/ml X-gal at 37 °C for 1 h or until sufficient blue staining develops. Syncytia were visualized under light microscope. TELCeB6 cells express endogenous β-gal; therefore, all TELCeB6 cells and syncytia were positively stained.
HIV antiviral assay
The antiviral assay was performed by infecting JC53-BL (TZM-bl) indicator cells with CCR5-tropic HIV NL-Bal virus (obtained from the NIH AIDS Research & Reagents Program). JC53-BL are Hela-derived cells that express a high level of CD4, CCR5, and CXCR4 and carry a long terminal repeat (LTR)-driven luciferase and an LTR-driven β-gal reporter. Briefly, CCR5 antagonists were serially diluted in 96-well plates. JC53-BL cells were added at 2.5 × 10 4 cells/well in DMEM containing 10% FBS, followed by the addition of NL-Bal virus. The infected cells were cultured at 37 °C for 3 days, then SteadyGlo luciferase substrate was added and the luciferase activity measured. Percentage inhibition of luciferase activity was calculated for each dose point after subtracting the background, and IC 50 was determined by using Excel XLfit.
FACS analysis
The expression of gp120, CD4, CCR5, and CXCR4 on various cells used in this study was examined by FACS. Cells were harvested and washed twice in PBS containing 0.5% FBS (FACS buffer) and then resuspended in FACS buffer at 4 × 10 6 cells/ml. For each reaction, 25 µl of cells (1 × 10 5 ) were transferred to a 5-ml tube and 1 µg of various primary antibodies and isotype controls were added, and the cells were incubated on ice for 30 to 45 min. Cells were washed 3 times in FACS buffer and incubated with PE-labeled antimouse secondary antibodies for 30 min on ice. At the end of incubation, cells were washed 3 times and resuspended in 300 µl of FACS buffer, and the stained cells were analyzed with a FACScan Calibur flow cytometer (Becton Dickinson, San Jose, CA).
Detection of pseudotyped viruses by Western blot
GP2-293Luc cells were transfected with R5-gp140, X4-gp140, X4-gp140X, or vector pcDNA3. Two days posttransfection, culture media were harvested and viral particles pelleted by centrifugation at 14,000 rpm for 30 min. The viruses were boiled in sample buffer containing 2% sodium dodecyl sulphate (SDS) and 5% 2-mercaptoethanol for 5 min, and viral proteins were resolved on a 7.5% SDS-polyacrylamide gel (NuPAGE Novex Bis Tris; Invitrogen, Carlsbad, CA), along with protein size markers (SeeBlue Plus; Invitrogen, Carlsbad, CA) and a recombinant gp120 control. Viral proteins on the gel were transferred onto nylon membranes and probed with mouse anti-HIV gp120 monoclonal antibody (1:500) and horseradish peroxidase (HRP)-conjugated secondary goat antimouse IgG antibody (1:1500). HIV gp120 protein bands were visualized by using enhanced chemiluminesence reagents (Pierce, Rockford, IL).
Statistical analysis of data
Linear regression analysis was performed by using Microsoft Excel, and coefficient R 2 values were generated to determine if a correlation existed between the 2 data sets.
RESULTS
Pseudotype antiviral assay design
A pseudotype antiviral assay was designed as depicted in Figure 1 . In this assay system, MMLV-HIVgp140 pseudotype viruses were produced by overexpressing the truncated form of HIV envelope protein gp140 (C-terminal 144 amino acid residues of gp41 were truncated) in GP2-293Luc packaging cell line. It was reported that HIV gp140 but not the full-length gp160 confers infectivity to the MMLV-HIVenv pseudotypes. 28 Because the tropism of these pseudotyped viruses is determined by the HIV envelope proteins, these pseudotypes can infect target cells expressing CD4 and CCR5 or CXCR4. GP2-293Luc packaging cells carrying an integrated luciferaseencoding retroviral vector can generate viral particles with luciferase transcripts packaged inside. Upon infection of host cells, luciferase will be made by the infected cells, and it can be measured. Two HIV gp140 expression constructs were generated for the production of pseudotypes carrying HIV envelopes that are either R5-tropic or X4-tropic. Even though it has been published that the CT-truncated form of HIV gp160 can efficiently mediate HIV-cell fusion, 18, 28 it is still necessary to test whether these gp140 glycoproteins derived from 92US715 (R5 virus) or NL-43 (X4 virus) retain their function in mediating viral entry. HIV gp140 glycoproteins were expressed in TELCeB6 cells by transient transfection, and the transfected cells were co-cultured with MAGI-R5 or MAGI-X4 cells. The co-cultures were stained for β-gal activity, and the positively stained TELCeB6 cells, which express endogenous β-gal and syncytia (fused multinuclei cells between TELCeB6 cells and MAGI cells) were visualized under microscope. As shown in Figure 2 , no syncytia formation was observed between pcDNA3-transfected TELCeB6 cells and MAGI-R5 or MAGI-X4 cells. However, syncytia were seen in co-cultures containing R5-gp140-transfected TELCeB6 cells and MAGI-R5 cells or X4-gp140-transfected TELCeB6 cells and MAGI-X4 cells. These results suggest that the CT-truncated HIV envelope protein gp140 retains its fusion function.
Development of pseudotype antiviral assays
An initial test of the pseudotype antiviral assay was carried out. Supernatants potentially containing pseudotyped MMLVHIVgp140 viral particles were added to MAGI-R5 or MAGI-X4 cells, and luciferase activity was measured 48 h postinfection. Low luciferase signal was detected when MAGI cells were infected with the appropriate viral supernatants. A variety of optimization approaches were tried to increase transfection efficiency or infectivity, but the luciferase signal was still low.
To determine if infectious pseudotyped MMLV-HIVgp140 viral particles were produced, TELCeB6 packaging cells that were previously proven to be able to generate infectious MMLVHIVenv pseudotypes 18 were used as control. Supernatants from R5-gp140 or X4-gp140 transfected TELCeB6 cultures were used to infect MAGI-R5 or MAGI-X4 cells, and the infected cells were stained for β-gal activity. TELCeB6 is a packaging cell line similar to GP2-293Luc, which produces nonenveloped MMLV particles. The main difference is that the viruses produced by TELCeB6 cells carry a β-gal mRNA whereas viruses produced from GP2-293Luc cells carry a luciferase mRNA. Therefore, by staining the infected MAGI cells, the presence of the MMLV-HIVgp140 pseudotypes can be visualized. As shown in Figure 3 , β-gal positively stained cells were found when MAGI-R5 cells were infected with supernatant derived from R5-gp140-transfected TELCeB6 cultures (Fig. 3B) ; similarly, positively stained cells were also observed when MAGI-X4 cells were infected with supernatant derived from X4-gp140-transfected TELCeB6 cultures (Fig. 3D) . No positively stained cells were observed when MAGI-R5 or MAGI-X4 cells were infected with supernatant derived from pcDNA3-transfected TELCeB6 cultures (Figs. 3A, C) . These data suggest that infectious pseudotyped MMLV-HIVgp140 viruses can be produced by the packaging cell line TELCeB6. However, it appears that the infection efficiency or viral titer is low (Figs. 3B, D) .
To troubleshoot the low luciferase signal generated from the infection of MAGI cells by pseudotyped MMLV-HIVgp140 viral supernatants, Western blot experiments were performed to detect pseudotypes in the culture supernatants. As shown in Figure 4A , HIV gp120 was detected from the pelleted pseudotyped viral particles derived from R5-gp140, X4-gp140, and X4-gp140K transfected GP2-293Luc culture supernatants. As a control, no gp120 was detectable from pcDNA3-transfected GP2-293Luc culture supernatant. These results demonstrated the production of expected pseudotyped viruses by GP2-293Luc cells upon overexpression of HIV gp140. Based on these results, we suspect that low luciferase signal probably was due to low infection efficiency. Several approaches were tried, and it was found that polybrene with spinoculation dramatically boosted the infection efficiency of MAGI-R5 cells by viral supernatants derived from R5-gp140-infected GP2-293Luc cells (Fig. 4B) . Treatment of the viral supernatants with 5 µg/ml polybrene increased the viral infection efficiency about 3-fold.
Centrifugation of polybrene-treated virus-cell cultures at room temperature for 45 min further increased the infection efficiency about 20-fold. Similar observation was also found for the infection of MAGI-X4 cells by viral supernatants derived from X4-gp140-infected GP2-293Luc cells (data not shown).
To determine the optimal amount of cells and viral supernatants in the pseudotype antiviral assays, various volumes of MMLV-HIVgp140(R5) viral supernatants were applied to MAGI-R5 cells, and spinoculation in the presence of 5 µg/ml polybrene was carried out. Luciferase activity in the infected cells dose dependently increased with the amount of viral supernatants (25-150 µl), and a linear correlation between the luciferase activity and the amount of viral supernatant was found (Fig. 4C) . Therefore, any viral dose between 25 µl and 150 µl can be used in the pseudotype antiviral assays. In most assays, 25 to 50 µl of viral supernatants was used. In addition, there was no significant difference between the infections of 5 × 10 3 and 1 × 10 4 cells/well of MAGI-R5 cells (Fig. 4C) . Although small variations were observed among viral stocks prepared on different dates, to keep the infections between each experiment consistent, large batches of viral supernatants were generated and stored at -80°C in aliquots. About a 3-fold reduction in infectivity was observed when frozen viral samples (single thaw) were used in the infection assays compared to fresh viral supernatants.
Effects of infection time on luciferase signal and entry inhibitors
The pseudotyped MMLV-HIVgp140 viruses carry RNA genomic transcripts encoding luciferase under the control of MMLV long-terminal repeats (LTR) promoter. Following infection, double-stranded DNA copies encoding luciferase may be generated and integrated into the host cell genome with the assistance of viral enzymes packaged inside the pseudotyped viral particles. Even though a certain amount of luciferase can be synthesized following infection, robust production of luciferase protein may need the generation of more luciferase transcript from the integrated viral genomic DNA. Therefore, there might be a delayed cumulative production of luciferase after infection. Initially, we performed the pseudotype infections for 24 h, and relatively low luciferase signal was observed. To determine the optimal infection time, MAGI-R5 cells were spin-infected with pseudotypes, and luciferase activity was measured at the end of various time periods. As show in Figure 5A , luciferase activity markedly increased with infection time during the first 2 days until it peaked at 48 h. The drug response of viral infection to the CCR5 antagonist SCH-C was independent of infection time (Fig. 5B) . The IC 50 s determined for SCH-C on pseudotype infections were very similar to each other for the 3 different infection time points 16 h, 24 h, and 48 h. Because no infectious viruses can be released from MAGI-R5 cells infected with the pseudotypes, the viral inhibition by any HIV entry inhibitors occurs only at the initial spin-infection step. Therefore, the infection rate of the MAGI cells in the presence of SCH-C remained the same for the different infection times, yet the luciferase signals were amplified proportionally with the increase of culture time. The 48-h infection time was used in all assays because it is the shortest time to yield maximal luciferase activity consistently.
Pseudotype antiviral assays are coreceptor specific
As mentioned above, the tropism of MMLV pseudotypes is dependent on the envelope proteins on the surface of the viruses. Therefore, the tropism of the MMLV-HIVgp140 pseudotypes is dependent on the tropism of the HIV envelope protein gp140. For instance, the MMLV virus pseudotyped with R5 HIVgp140 will be able to infect target cells that express CCR5; the MMLV virus pseudotyped with X4 HIVgp140 will be able to infect target cells that express CXCR4. To demonstrate this coreceptorspecific infection of the MMLV-HIVgp140 pseudotypes, MAGI-R5 and MAGI-X4 cells were infected with pseudotyped viruses carrying either R5-gp140 or X4-gp140. As shown in Figure 6 , pseudotyped virus MMLV-HIVgp140(R5) was able to efficiently infect MAGI-R5 but not MAGI-X4 cells; in contrast, MMLV-HIVgp140(X4) was able to efficiently infect MAGI-X4 but not MAGI-R5 cells. These results demonstrated that these MMLV-HIVenv pseudotypes are highly coreceptor dependent, thus making them very useful in evaluating HIV coreceptor inhibitors.
Validation of pseudotype antiviral assays
To further validate the specificity and accuracy of the CCR5-and CXCR4-dependent pseudotype antiviral assays, several known HIV entry inhibitors targeting various stages of the entry process were tested. The IC 50 s determined in these assays were found to be consistent with published antiviral data ( Table 1) . Standard sigmoid inhibition curves were observed for all active inhibitors, suggesting proper drug responses and true IC 50 values (Fig. 7) . Furthermore, infections of MAGI cells by R5 or X4 pseudotypes were specifically inhibited by the corresponding inhibitors. HIV fusion inhibitor ENF inhibited both CCR5-dependent and CXCR4-dependent pseudotype infections. CCR5 antagonists SCH-D, AK602, TAK-779, and MVC, as well as CCR5 monoclonal antibody 2D7, inhibited only R5 pseudotypes; CXCR4 antagonists T-22 and AMD3100 inhibited only X4 pseudotypes. These results further demonstrate that these pseudotype antiviral assays are highly coreceptor specific. 
Evaluation of CCR5 antagonists by using R5-pseudotype antiviral assay
Hundreds of small-molecule CCR5 antagonists were tested in the R5-pseudotype antiviral assay as well as in HIV antiviral assays and CCF assays. IC 50 values determined in these assays were compared. As shown in the scatter plot (Fig. 8A) , most of the IC 50 values for the 70 CCR5 antagonists are located in the center zone, suggesting a good correlation of IC 50 values determined by the pseudotype antiviral assay and the HIV antiviral assay. A high R 2 value (0.903) for these 2 sets of IC 50 value groups was observed. Similarly, IC 50 values for a total of 111 CCR5 antagonists derived from CCF assay and pseudotype antiviral assay were also analyzed. A good correlation was also observed between them, with an R 2 value of 0.799 (Fig. 8B) . In addition, this high correlation between pseudotype antiviral assay and HIV antiviral assay or CCF assay was found true for a wide range of IC 50 values (1 nM to 50 µM), suggesting that the pseudotype antiviral assay can be used to detect CCR5 inhibitors of a wide range of antiviral potency with good accuracy. Therefore, these data, together with the IC 50 data for various known HIV entry inhibitors, have validated the pseudotype antiviral assay system as a powerful surrogate assay for identifying and characterizing HIV entry inhibitors.
DISCUSSION
Here we report a novel anti-HIV assay system using luciferase-bearing pseudotyped MMLV-HIVenv viruses. The pseudotyped viruses were efficiently produced by GP2-293Luc cells transfected with HIV gp140 expression plasmids. The MMLV viruses can be pseudotyped with both R5 and X4 HIV envelope proteins that determine the tropism of the pseudotypes. Therefore, this dual R5-specific and X4-specific pseudotype single-cycle antiviral assay system is especially useful in characterizing CCR5 or CXCR4 inhibitors. Interestingly, much lower luciferase signal was detected for the X4 pseudotypeinfected MAGI-X4 cells than the R5 pseudotype-infected MAGI-R5 cells (Fig. 6) . The reason for this is not clear. Based on the Western blot data, it seems that the production of R5 pseudotypes is similar to that of X4 pseudotypes. However, the molecular size of the R5-gp120 on the pseudotyped viral particles is slightly larger than that of the X4-gp120. It is not clear if the size difference is due to their difference in extent of glycosylation or other modifications because the predicted protein size is almost identical between the gp120s from R5 strain 92US715 and X4 strain NL43. HIV envelope protein gp120 is heavily glycosylated, and this modification may be important in CD4 and coreceptor recognition and antibody neutralization. It was reported that the expression level of coreceptors can greatly influence the virus-cell fusion kinetics. 29 However, the expression levels of CCR5 on MAGI-R5 cells and CXCR4 on MAGI-X4 cells were comparable as demonstrated by FACS analysis (data not shown). Because there is no evidence showing that R5 HIV viruses infect more efficiently than X4 viruses do in engineered cells that overexpress coreceptors, it is likely that the difference in infection efficiency between an R5 and an X4 pseudotyped virus is strain related. However, testing of more R5 and X4 pseudotypes is necessary for drawing any conclusion. To boost the production of the X4 pseudotypes, approaches have been tried to increase expression of X4 gp140 envelope proteins. The expression and final presentation of HIV envelope proteins is a complex process that can be influenced by many factors. Because the same HIV genomic regions from the R5 and X4 viruses were cloned into the same expression vector, one potential site of modifications is the translation initiation. In an attempt to enhance the translation efficiency of the X4-gp140, a Kozak sequence was incorporated into the gp140 translation start site. However, this modification did not significantly increase the production of X4-gp140-pseudotyped MMLV particles (Fig. 4A) . Although the luciferase signal of the X4-pseudotype antiviral assay is relatively low, it still provides a signal-to-background ratio of about 50, providing enough sensitivity for accurate measurement of full-dose responses of CXCR4 antagonists and fusion inhibitor (Fig. 7B) .
Full-length HIV envelope proteins have been successfully pseudotyped with HIV Gag and Pol. 17 However, there is no success yet in pseudotyping viruses from other families with fulllength HIV envelope proteins. Rabies virus was pseudotyped with HIV envelope proteins whose cytoplasmic domain was replaced with that of the rabies virus G protein. 30 Data from this study and previous reports demonstrate that the MMLV virus can be pseudotyped with HIV envelope proteins lacking CT. 28 HIV envelope protein gp41 has an unusually long CT of approximately 150 amino acids, whereas other retroviral transmembrane proteins generally comprise 22 to 38 amino acids. Therefore, the exceptionally long cytoplasmic domain of HIV gp41, which is ultimately located in the interior of the virion, likely interferes with viral capsid or core formation and thus prevents particle assembly of MMLV or other pseudotyping viruses. Besides, one important question to ask when using the MMLV-HIVgp140 pseudotypes to infect HIV host cells is whether the truncated HIV envelope proteins can mediate normal virus-cell fusion. The HIV and simian immunodeficiency virus (SIV) CTs contain a number of functional domains: a YxxØ (Ø = amino acids with a bulky hydrophobic side chain) motif that mediates binding to AP2 µ chains, clathrin-dependent endocytosis, and basolateral sorting of Env in polarized cells [30] [31] [32] ; 1 or more palmitoylated cysteines implicated in targeting Env to lipid rafts [33] [34] [35] ; and 3 highly conserved α-helical lentivirus lytic peptide (LLP) domains (LLP-1, LLP-2, and LLP-3) implicated in interacting with the plasma membrane, decreasing bilayer stability, and altering membrane ionic permeability. 36 Other regions of gp41 have also been implicated in interacting with viral matrix proteins during virion assembly. 35 Published data indicate that point mutations or truncations in the CT of HIV or SIV can increase Env fusogenicity and surface expression, [8] [9] [10] [11] whereas Env incorporation into virions can be increased or decreased. 10 In addition, CT truncations are also associated with CD4-independent infection of some HIV variants. 37 Our own data also suggest that the CT-truncated gp41 mediates cell-cell fusion as well as or superior to its full-length counterpart (data not shown). In the current study, MMLVHIVgp140 pseudotypes produced by both TELCeB6 and GP2-293Luc cells were fully functional in infecting HIV host cells. More important, the anti-HIV assays based on these pseudotypes were well validated by using a variety of known HIV entry inhibitors, despite any potential difference in fusion efficiency or kinetics between HIV-cell fusion and MMLV-HIVgp140-cell fusion. Besides, changes in the expression levels of HIV envelope proteins appear to affect virus-cell fusion efficiency but not fusion kinetics. 38 HIV enters host cells via specific interactions with CD4 and chemokine receptor CCR5 or CXCR4. Published evidence suggests that HIV initiates interaction with host cells through binding to other cell surface molecules as well. These cell membrane proteins include heparin sulfate-containing proteoglycans 39 and the dendritic cell-specific intercellular adhesion molecule 3 binding C-type lectin. 40 Polybrene is a small, positively charged molecule that binds to cell surfaces and neutralizes surface charge. This apparently allows the viral glycoproteins to bind more efficiently to their receptors because it reduces the repulsion between sialic acid-containing molecules. It has long been realized that polycationic reagents such as polybrene can aid viral infection processes in vitro by facilitating viral attachment to cell surface. 41 Because polybrene is highly toxic for cells and can be used only at concentrations below 20 µg/ml, 5 µg/ml concentration of polybrene was used in this study, and about a 3-fold increase in infection efficiency was obtained (Fig. 4B) . To further enhance pseudotype infection, spinoculation (spin inoculation) was used, which resulted in a 20-fold further increase of infection efficiency of MMLV-HIVgp140 viruses (Fig. 4B) . Although spinoculation has been used in clinical microbiology since the 1950s to enhance infectivity of a number of difficult-to-culture pathogens, including HIV-1 and other retroviruses, [42] [43] [44] the mechanism whereby centrifugation enhances viral infection remains controversial. The majority of published data support the hypothesis that centrifugation enhances either viral deposition on the cell surface or viral fusion. 42, 43 Moreover, it appears that the spin-enhanced virion deposition is in a CD4-dependent manner. 42 Therefore, the use of an infection-facilitating agent or approaches does not seem to cause nonspecific viral infection. This is confirmed by the findings from the current study that centrifugal infection of MAGI cells by R5 or X4 pseudotypes is coreceptor specific.
The MMLV-HIVenv pseudotype-based anti-HIV assay previously reported by Kim and others uses β-gal as the reporter, and the readout is by visual inspection of infected cells (β-gal positive cells). 18, 19 However the assay described demonstrated low sensitivity and employs a quantitation format that is not suitable for medium-or high-throughput screening (HTS) for entry inhibitors. When we infected MAGI cells with MMLVHIVgp140 pseudotypes produced from the same packaging cell line TELCeB6 that was used by Kim and others, fewer than 1% of the cells were infected (Fig. 3) . When the β-gal activity of the infected cultures was measured using a commercial β-gal assay kit by quantitation of cell lysates, no detectable β-gal activity was observed (data not shown). A luciferase reporter system generally shows a broader dynamic range than the β-gal reporter system. Here, we reported an improved MMLV-HIVgp140 pseudotype antiviral assay system using luciferase as the reporter that can be transferred into infected cells. With the addition of polybrene and use of spinoculation, robust luciferase signal was detected, which is viral supernatant dose dependent. This assay system comprises both R5-specific and X4-specific antiviral assays; thus, it is particularly useful in assessing HIV coreceptor inhibitors. This pseudotype-based antiviral assay is simple, quick, and biologically similar to HIV antiviral assays yet very safe. Therefore, it can be used as a surrogate antiviral assay for routine identification and characterization of novel HIV entry inhibitors. Although the HIV-HIVenv pseudotype single-cycle antiviral assay can be used for the detection of all anti-HIV agents, 17, 45 this MMLV-based anti-HIV assay system is specifically designed for HIV entry inhibitors. Therefore, this novel MMLV-HIVenv antiviral assay system can be used for HTS of novel inhibitors that target various viral entry steps.
